相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
V. Gopalakrishnan et al.
SCIENCE (2018)
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Bertrand Routy et al.
SCIENCE (2018)
Regulatory T cells in cancer immunotherapy
Atsushi Tanaka et al.
CELL RESEARCH (2017)
Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition
Jiangtao Ren et al.
CLINICAL CANCER RESEARCH (2017)
Tumour-associated mesenchymal stem/stromal cells: emerging therapeutic targets
Yufang Shi et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
Daniel Sanghoon Shin et al.
CANCER DISCOVERY (2017)
Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer
Valsamo Anagnostou et al.
CANCER DISCOVERY (2017)
Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors
Frederick Arce Vargas et al.
IMMUNITY (2017)
Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer
Nicholas A. Taylor et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
New development in CAR-T cell therapy
Zhenguang Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy
Bingshan Liu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
De-novo and acquired resistance to immune checkpoint targeting
Nicholas L. Syn et al.
LANCET ONCOLOGY (2017)
Epigenetics and immunotherapy: The current state of play
Jennifer Dunn et al.
MOLECULAR IMMUNOLOGY (2017)
Identification of CMTM6 and CMTM4 as PD-L1 protein regulators
Riccardo Mezzadra et al.
NATURE (2017)
Therapeutic T cell engineering
Michel Sadelain et al.
NATURE (2017)
Elements of cancer immunity and the cancer-immune set point
Daniel S. Chen et al.
NATURE (2017)
CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity
Marian L. Burr et al.
NATURE (2017)
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
Sydney R. Gordon et al.
NATURE (2017)
Monitoring immune-checkpoint blockade: response evaluation and biomarker development
Mizuki Nishino et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy
Sean P. Arlauckas et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes
Jingjing Zhu et al.
NATURE COMMUNICATIONS (2017)
Resistance to checkpoint blockade therapy through inactivation of antigen presentation
Moshe Sade-Feldman et al.
NATURE COMMUNICATIONS (2017)
Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma
Jon Bjoern et al.
ONCOTARGET (2017)
Combined Anti-VEGF and Anti-CTLA-4 Therapy Elicits Humoral Immunity to Galectin-1 Which Is Associated with Favorable Clinical Outcomes
Xinqi Wu et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Myeloid-Derived Suppressor Cells
Dmitry I. Gabrilovich
CANCER IMMUNOLOGY RESEARCH (2017)
Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells
Zibing Wang et al.
ONCOIMMUNOLOGY (2017)
Tumor-infiltrating CD39+ γδTregs are novel immunosuppressive T cells in human colorectal cancer
Guoming Hu et al.
ONCOIMMUNOLOGY (2017)
Immunotherapy in ovarian, endometrial and cervical cancer: State of the art and future perspectives
Jole Ventriglia et al.
CANCER TREATMENT REVIEWS (2017)
γδ T Cells: Unexpected Regulators of Cancer Development and Progression
Christopher Fleming et al.
TRENDS IN CANCER (2017)
De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation
Hazem E. Ghoneim et al.
CELL (2017)
Hallmarks of response to immune checkpoint blockade
Alexandria P. Cogdill et al.
BRITISH JOURNAL OF CANCER (2017)
Metabolic Instruction of Immunity
Michael D. Buck et al.
CELL (2017)
Prospects for combining targeted and conventional cancer therapy with immunotherapy
Philip Gotwals et al.
NATURE REVIEWS CANCER (2017)
Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers
Robbie G. Majzner et al.
CANCER CELL (2017)
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Laurence P. Diggs et al.
BIOMARKER RESEARCH (2017)
The Principles of Engineering Immune Cells to Treat Cancer
Wendell A. Lim et al.
CELL (2017)
Immunogenic cell death in cancer and infectious disease
Lorenzo Galluzzi et al.
NATURE REVIEWS IMMUNOLOGY (2017)
Immunometabolism governs dendritic cell and macrophage function
Luke A. J. O'Neill et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2016)
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
Weiyi Peng et al.
CANCER DISCOVERY (2016)
Microbiome and Anticancer Immunosurveillance
Laurence Zitvogel et al.
CELL (2016)
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
Jianjun Gao et al.
CELL (2016)
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Willy Hugo et al.
CELL (2016)
γδ T Cells Support Pancreatic Oncogenesis by Restraining αβ T Cell Activation
Donnele Daley et al.
CELL (2016)
HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma
Hong Zheng et al.
CLINICAL CANCER RESEARCH (2016)
Bioenergetic Insufficiencies Due to Metabolic Alterations Regulated by the Inhibitory Receptor PD-1 Are an Early Driver of CD8+ T Cell Exhaustion
Bertram Bengsch et al.
IMMUNITY (2016)
Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family
Frank A. Schildberg et al.
IMMUNITY (2016)
BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models
Yuki Kagoya et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Case report: mismatch repair proficiency and microsatellite stability in gastric cancer may not predict programmed death-1 blockade resistance
Kuo-Hsing Chen et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
Weijie Ma et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Emerging therapeutic agents for lung cancer
Bhagirathbhai Dholaria et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
F. Stephen Hodi et al.
LANCET ONCOLOGY (2016)
Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells
Olivier De Henau et al.
NATURE (2016)
PI3Kγ is a molecular switch that controls immune suppression
Megan M. Kaneda et al.
NATURE (2016)
Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers
Takuro Saito et al.
NATURE MEDICINE (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
HDAC inhibitors with PD-1 blockade: a promising strategy for treatment of multiple cancer types?
Amer A. Beg et al.
EPIGENOMICS (2016)
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
Shohei Koyama et al.
NATURE COMMUNICATIONS (2016)
Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model
Eloah Rabello Suarez et al.
ONCOTARGET (2016)
Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab
Jeffrey Weber et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma
Marcel A. Deken et al.
ONCOIMMUNOLOGY (2016)
From Krebs to clinic: glutamine metabolism to cancer therapy
Brian J. Altman et al.
NATURE REVIEWS CANCER (2016)
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Suzanne L. Topalian et al.
CANCER CELL (2015)
ER Stress Sensor XBP1 Controls Anti-tumor Immunity by Disrupting Dendritic Cell Homeostasis
Juan R. Cubillos-Ruiz et al.
CELL (2015)
Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses
Ping-Chih Ho et al.
CELL (2015)
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
Chih-Hao Chang et al.
CELL (2015)
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
Padmanee Sharma et al.
CELL (2015)
Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab
Christoffer Gebhardt et al.
CLINICAL CANCER RESEARCH (2015)
Cancer immunotherapy: harnessing the immune system to battle cancer
Yiping Yang
JOURNAL OF CLINICAL INVESTIGATION (2015)
T cell metabolism drives immunity
Michael D. Buck et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
CTLA-4 Blockade Plus Adoptive T-Cell Transfer Promotes Optimal Melanoma Immunity in Mice
David A. Mahvi et al.
JOURNAL OF IMMUNOTHERAPY (2015)
Enhancing Antitumor Efficacy of Chimeric Antigen Receptor T Cells Through Constitutive CD40L Expression
Kevin J. Curran et al.
MOLECULAR THERAPY (2015)
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Christina Twyman-Saint Victor et al.
NATURE (2015)
Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
Dongjun Peng et al.
NATURE (2015)
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Stefani Spranger et al.
NATURE (2015)
4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
Adrienne H. Long et al.
NATURE MEDICINE (2015)
Combination cancer immunotherapy and new immunomodulatory targets
Kathleen M. Mahoney et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Big opportunities for small molecules in immuno-oncology
Jerry L. Adams et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Generation of knock-in primary human T cells using Cas9 ribonucleoproteins
Kathrin Schumann et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy
Ayelet Sivan et al.
SCIENCE (2015)
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Eliezer M. Van Allen et al.
SCIENCE (2015)
T cell exclusion, immune privilege, and the tumor microenvironment
Johanna A. Joyce et al.
SCIENCE (2015)
Immunogenicity of somatic mutations in human gastrointestinal cancers
Eric Tran et al.
SCIENCE (2015)
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Marie Vetizou et al.
SCIENCE (2015)
The future of immune checkpoint therapy
Padmanee Sharma et al.
SCIENCE (2015)
Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAFV600E melanoma
Siwen Hu-Lieskovan et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Overcoming T cell exhaustion in infection and cancer
Kristen E. Pauken et al.
TRENDS IN IMMUNOLOGY (2015)
PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation
Nikolaos Patsoukis et al.
NATURE COMMUNICATIONS (2015)
Decitabine Enhances Lymphocyte Migration and Function and Synergizes with CTLA-4 Blockade in a Murine Ovarian Cancer Model
Lei Wang et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors
Daniela S. Thommen et al.
CANCER IMMUNOLOGY RESEARCH (2015)
CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer
Tomoe Higuchi et al.
CANCER IMMUNOLOGY RESEARCH (2015)
HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade
David M. Woods et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Role of Local Radiation Therapy in Cancer Immunotherapy
Sandra Demaria et al.
JAMA ONCOLOGY (2015)
Vaccine-Induced Tumor Necrosis Factor-Producing T Cells Synergize with Cisplatin to Promote Tumor Cell Death
Tetje C. van der Sluis et al.
CLINICAL CANCER RESEARCH (2015)
Combination Therapy with Anti-CTLA-4 and Anti-PD-1 Leads to Distinct Immunologic Changes In Vivo
Rituparna Das et al.
JOURNAL OF IMMUNOLOGY (2015)
Reversible Inhibitors of LSD1 as Therapeutic Agents in Acute Myeloid Leukemia: Clinical Significance and Progress to Date
Daniel P. Mould et al.
MEDICINAL RESEARCH REVIEWS (2015)
The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints
Nicolas J. Llosa et al.
CANCER DISCOVERY (2015)
Molecular and cellular insights into T cell exhaustion
E. John Wherry et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Immune Modulation in Cancer with Antibodies
David B. Page et al.
ANNUAL REVIEW OF MEDICINE, VOL 65 (2014)
CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer Models
Yu Zhu et al.
CANCER RESEARCH (2014)
The Glucose Transporter Glut1 Is Selectively Essential for CD4 T Cell Activation and Effector Function
Andrew N. Macintyre et al.
CELL METABOLISM (2014)
Molecular Pathways: Myeloid Complicity in Cancer
Ingunn M. Stromnes et al.
CLINICAL CANCER RESEARCH (2014)
γδT17 Cells Promote the Accumulation and Expansion of Myeloid-Derived Suppressor Cells in Human Colorectal Cancer
Pin Wu et al.
IMMUNITY (2014)
The Transcription Factor FoxO1 Sustains Expression of the Inhibitory Receptor PD-1 and Survival of Antiviral CD8+ T Cells during Chronic Infection
Matthew M. Staron et al.
IMMUNITY (2014)
Interplay between regulatory T cells and PD-1 in modulating T cell exhaustion and viral control during chronic LCMV infection
Pablo Penaloza-MacMaster et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial
Jason R. Westin et al.
LANCET ONCOLOGY (2014)
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
Eugene D. Kwon et al.
LANCET ONCOLOGY (2014)
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Matthew M. Gubin et al.
NATURE (2014)
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Alexandra Snyder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells
KiBem Kim et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy
Steven L. Highfill et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
γδ T cell surveillance via CD1 molecules
Adrienne M. Luoma et al.
TRENDS IN IMMUNOLOGY (2014)
Paradoxical Activation of T Cells via Augmented ERK Signaling Mediated by a RAF Inhibitor
Margaret K. Callahan et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Pretreatment Serum VEGF Is Associated with Clinical Response and Overall Survival in Advanced Melanoma Patients Treated with Ipilimumab
Jianda Yuan et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade
Zachary A. Cooper et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Cancer vaccines in the world of immune suppressive monocytes (CD14+HLA-DRI lo/neg cells): the gateway to improved responses
Rebecca R. Laborde et al.
FRONTIERS IN IMMUNOLOGY (2014)
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment
Stefani Spranger et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study
S. F. Slovin et al.
ANNALS OF ONCOLOGY (2013)
Tumor-associated macrophages as potential diagnostic and prognostic biomarkers in breast cancer
Xiaoqiang Tang
CANCER LETTERS (2013)
Posttranscriptional Control of T Cell Effector Function by Aerobic Glycolysis
Chih-Hao Chang et al.
CELL (2013)
BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
Dennie T. Frederick et al.
CLINICAL CANCER RESEARCH (2013)
Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells
Liza B. John et al.
CLINICAL CANCER RESEARCH (2013)
Combining cancer immunotherapy and targeted therapy
Antoni Ribas et al.
CURRENT OPINION IN IMMUNOLOGY (2013)
Deciphering and Reversing Tumor Immune Suppression
Greg T. Motz et al.
IMMUNITY (2013)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors
Deborah A. Knight et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Control of inflammation by integration of environmental cues by regulatory T cells
Ashutosh Chaudhry et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
KIT oncogene inhibition drives intratumoral macrophage M2 polarization
Michael J. Cavnar et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Antitumor Effect of Paclitaxel Is Mediated by Inhibition of Myeloid-Derived Suppressor Cells and Chronic Inflammation in the Spontaneous Melanoma Model
Alexandra Sevko et al.
JOURNAL OF IMMUNOLOGY (2013)
Hepatotoxicity with Combination of Vemurafenib and Ipilimumab
Antoni Ribas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia
Stephan A. Grupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment
Noriho Iida et al.
SCIENCE (2013)
Fueling Immunity: Insights into Metabolism and Lymphocyte Function
E. L. Pearce et al.
SCIENCE (2013)
The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide
Sophie Viaud et al.
SCIENCE (2013)
Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
Stefani Spranger et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Alterations of immune response of non-small cell lung cancer with Azacytidine
John Wrangle et al.
ONCOTARGET (2013)
Severe Cutaneous and Neurologic Toxicity in Melanoma Patients during Vemurafenib Administration Following Anti-PD-1 Therapy
Douglas B. Johnson et al.
CANCER IMMUNOLOGY RESEARCH (2013)
An Abscopal Response to Radiation and Ipilimumab in a Patient with Metastatic Non-Small Cell Lung Cancer
Encouse B. Golden et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Human Vδ2 versus non-Vδ2 γδ T cells in antitumor immunity
Dieter Kabelitz et al.
ONCOIMMUNOLOGY (2013)
Emerging Co-signaling Networks in T Cell Immune Regulation
Keunok Jung et al.
Immune Network (2013)
History of myeloid-derived suppressor cells
James E. Talmadge et al.
NATURE REVIEWS CANCER (2013)
Molecular mechanisms of T cell co-stimulation and co-inhibition
Lieping Chen et al.
NATURE REVIEWS IMMUNOLOGY (2013)
Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning
Hollie J. Pegram et al.
BLOOD (2012)
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Douglas Hanahan et al.
CANCER CELL (2012)
Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
Seng-Ryong Woo et al.
CANCER RESEARCH (2012)
Regulatory T-cell Modulation Using Cyclophosphamide in Vaccine Approaches: A Current Perspective
Dung T. Le et al.
CANCER RESEARCH (2012)
PD-1 Blockade Enhances T-cell Migration to Tumors by Elevating IFN-γ Inducible Chemokines
Weiyi Peng et al.
CANCER RESEARCH (2012)
Densely Granulated Murine NK Cells Eradicate Large Solid Tumors
Rebecca B. Liu et al.
CANCER RESEARCH (2012)
T-Regulatory Cells: Key Players in Tumor Immune Escape and Angiogenesis
Andrea Facciabene et al.
CANCER RESEARCH (2012)
Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non-Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
Thomas J. Lynch et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Blockade of Myeloid-Derived Suppressor Cells after Induction of Lymphopenia Improves Adoptive T Cell Therapy in a Murine Model of Melanoma
Krithika N. Kodumudi et al.
JOURNAL OF IMMUNOLOGY (2012)
Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?
Joannes F. M. Jacobs et al.
LANCET ONCOLOGY (2012)
Tumor PD-L1 co-stimulates primary human CD8+ cytotoxic T cells modified to express a PD1:CD28 chimeric receptor
Megan E. Prosser et al.
MOLECULAR IMMUNOLOGY (2012)
The functions and regulation of the PTEN tumour suppressor
Min Sup Song et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2012)
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
Fei Su et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
Janis M. Taube et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
BRAF inhibition improves tumor recognition by the immune system Potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer
Marco Donia et al.
ONCOIMMUNOLOGY (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells
Samantha Solito et al.
BLOOD (2011)
β-Catenin Signaling Controls Metastasis in Braf-Activated Pten-Deficient Melanomas
William E. Damsky et al.
CANCER CELL (2011)
Prerequisites for the Antitumor Vaccine-Like Effect of Chemotherapy and Radiotherapy
Dalil Hannani et al.
CANCER JOURNAL (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients
Ingrid M. E. Desar et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma
Evan M. Hersh et al.
INVESTIGATIONAL NEW DRUGS (2011)
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
Omid Hamid et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2011)
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
Vinod P. Balachandran et al.
NATURE MEDICINE (2011)
Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases
Peter Carmeliet et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia
David L. Porter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
Robert D. Schreiber et al.
SCIENCE (2011)
Combination Epigenetic Therapy Has Efficacy in Patients with Refractory Advanced Non-Small Cell Lung Cancer
Rosalyn A. Juergens et al.
CANCER DISCOVERY (2011)
Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts
Sid P. Kerkar et al.
CANCER RESEARCH (2010)
5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell-Dependent Antitumor Immunity
Julie Vincent et al.
CANCER RESEARCH (2010)
Regulatory T cells and immune tolerance to tumors
Xuefang Cao
IMMUNOLOGIC RESEARCH (2010)
Abrogating Cbl-b in effector CD8+ T cells improves the efficacy of adoptive therapy of leukemia in mice
Ingunn M. Stromnes et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Renal Cancer Resistance to Antiangiogenic Therapy Is Delayed by Restoration of Angiostatic Signaling
Rupal S. Bhatt et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm
Subhra K. Biswas et al.
NATURE IMMUNOLOGY (2010)
Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells
Francois Romagne et al.
BLOOD (2009)
Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients
Jennifer S. Ko et al.
CLINICAL CANCER RESEARCH (2009)
Cell-Intrinsic Transforming Growth Factor-β Signaling Mediates Virus-Specific CD8+ T Cell Deletion and Viral Persistence In Vivo
Roberto Tinoco et al.
IMMUNITY (2009)
Human peripheral γδ T cells possess regulatory potential
Anja A. Kuehl et al.
IMMUNOLOGY (2009)
Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1
Dong-Ming Kuang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
Loise M. Francisco et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies
Karl S. Peggs et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation
G. Solinas et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2009)
Myeloid-derived suppressor cells as regulators of the immune system
Dmitry I. Gabrilovich et al.
NATURE REVIEWS IMMUNOLOGY (2009)
Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis
Li Yang et al.
CANCER CELL (2008)
The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients
Takuya Osada et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
The anticancer immune response: indispensable for therapeutic success?
Laurence Zitvogel et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
IL-10 and PD-L1 operate through distinct pathways to suppress T-cell activity during persistent viral infection
David G. Brooks et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)
Michal Marzec et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
CTLA-4 control over Foxp3+ regulatory T cell function
Kajsa Wing et al.
SCIENCE (2008)
Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells
Monica V. Goldberg et al.
BLOOD (2007)
Chromatin modifications and their function
Tony Kouzarides
CELL (2007)
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients
Tracy T. Batchelor et al.
CANCER CELL (2007)
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
Andrew T. Parsa et al.
NATURE MEDICINE (2007)
Apoptosis signaling pathways and lymphocyte homeostasis
Guangwu Xu et al.
CELL RESEARCH (2007)
Cancer epigenomics: DNA methylomes and histone-modification maps
Manel Esteller
NATURE REVIEWS GENETICS (2007)
Resolution of a chronic viral infection after interleukin-10 receptor blockade
Mette Ejrnaes et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Cancer despite immunosurveillance: immunoselection and immunosubversion
Laurence Zitvogel et al.
NATURE REVIEWS IMMUNOLOGY (2006)
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells
Sergio A. Quezada et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4
Kimberly E. Beck et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma
I Kryczek et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms
RV Parry et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity
E Suzuki et al.
CLINICAL CANCER RESEARCH (2005)
IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression
GP Dunn et al.
CANCER RESEARCH (2005)
Regulatory T cell lineage specification by the forkhead transcription factor FoxP3
JD Fontenot et al.
IMMUNITY (2005)
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
CG Willett et al.
NATURE MEDICINE (2004)
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
TJ Curiel et al.
NATURE MEDICINE (2004)
Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses
PC Rodriguez et al.
CANCER RESEARCH (2004)
Expansion of myeloid immune suppressor Gr+CD11b+cells in tumor-bearing host directly promotes tumor angiogenesis
L Yang et al.
CANCER CELL (2004)
Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes
A Mantovani et al.
TRENDS IN IMMUNOLOGY (2002)
Cancer immunoediting: from immunosurveillance to tumor escape
GP Dunn et al.
NATURE IMMUNOLOGY (2002)
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Y Iwai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase
DH Munn et al.
SCIENCE (2002)
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
HD Dong et al.
NATURE MEDICINE (2002)
The interaction properties of costimulatory molecules revisited
AV Collins et al.
IMMUNITY (2002)
The fundamental role of epigenetic events in cancer
PA Jones et al.
NATURE REVIEWS GENETICS (2002)
Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity
A Diefenbach et al.
NATURE (2001)
分享论文
